Protective role of STING against gliomagenesis: Rational use of STING agonist in anti-glioma immunotherapy

Takayuki Ohkuri; Arundhati Ghosh; Akemi Kosaka; Saumendra N Sarkar; Hideho Okada

doi:10.1080/2162402X.2014.999523

Protective role of STING against gliomagenesis: Rational use of STING agonist in anti-glioma immunotherapy

Oncoimmunology. 2015 Jan 22;4(4):e999523. doi: 10.1080/2162402X.2014.999523. eCollection 2015 Apr.

Authors

Takayuki Ohkuri¹, Arundhati Ghosh², Akemi Kosaka¹, Saumendra N Sarkar³, Hideho Okada⁴

Affiliations

¹ Department of Pathology, Asahikawa Medical University , Asahikawa, Japan.
² Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine , Pittsburgh, PA USA ; Cancer Virology Program, University of Pittsburgh Cancer Institute , Pittsburgh, PA USA.
³ Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine , Pittsburgh, PA USA ; Department of Immunology, University of Pittsburgh School of Medicine , Pittsburgh, PA USA ; Cancer Virology Program, University of Pittsburgh Cancer Institute , Pittsburgh, PA USA.
⁴ Department of Neurosurgery, University of California San Francisco , San Francisco, CA USA.

Abstract

We recently reported that STING contributes to antiglioma immunity by triggering type I IFN induction in glioma microenvironment. Moreover, intratumoral administration of STING agonist improved the efficacy of peptide vaccination in a mouse glioma model, suggesting the rational use of STING agonists in the immunotherapy of brain tumor.

Keywords: Immunotherapy; STING; glioma; type I IFNs.

Grants and funding

R01 NS055140/NS/NINDS NIH HHS/United States